Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.

Publication Type:

Journal Article

Source:

The lancet oncology, Volume 14, Issue 10, p.999-1008 (2013)

Keywords:

2013, Adolescent, Adult, Child, Child, Preschool, Clinical Research Division, Disease-Free Survival, Humans, Immunomagnetic Separation, Infant, Neuroblastoma, October 2013, Peripheral Blood Stem Cell Transplantation, RISK

Abstract:

Myeloablative chemoradiotherapy and immunomagnetically purged autologous bone marrow transplantation has been shown to improve outcome for patients with high-risk neuroblastoma. Currently, peripheral blood stem cells (PBSC) are infused after myeloablative therapy, but the effect of purging is unknown. We did a randomised study of tumour-selective PBSC purging in stem-cell transplantation for patients with high-risk neuroblastoma.